Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the UBS Virtual Ophthalmology Day.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the UBS Virtual Ophthalmology Day. The company will host a fireside chat on Wednesday, October 2, 2024, at 8:30 a.m. ET. This event will be accessible through a live webcast on the company's website, specifically on the "Events and Presentations" page within the "Investors and Media" section.
For those unable to attend the live event, Apellis will provide a replay of the webcast, which will remain available for approximately 90 days following the event. This virtual participation underscores Apellis' commitment to engaging with investors and industry professionals in the ophthalmology sector.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -0.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the UBS Virtual Ophthalmology Day on Wednesday, October 2, 2024, at 8:30 a.m. ET.
The live event webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.